Skip to content

Virtual Reality in Occupational Therapy Upper Limb Stroke Rehabilitation

The Feasibility of Implementing Virtual Reality-based Upper Limb Rehabilitation for Stroke Patients and Occupational Therapists in an Acute Stroke Unit and Community Stroke Team, in Terms of Technology Acceptance, Safety and Usability

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07032155
Enrollment
30
Registered
2025-06-22
Start date
2025-07-01
Completion date
2025-12-31
Last updated
2025-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

The study aims to assess the feasibility of using Resynk, a virtual reality (VR) software platform for upper limb rehabilitation for stroke survivors, both in acute hospital settings and in the community (home, private nursing home, residential home). Resynk offers interactive, task-oriented training that enhances therapy intensity and patient motivation. Previous findings from a Quality Improvement project showed significant increases in treatment intensity and patient engagement with Resynk. This study will explore barriers to Resynk implementation and gather input from staff participants and stroke survivors to ensure successful integration and effectiveness. Resynk will be delivered alongside standard care, with no intention to delay or reduce existing rehabilitation services. The study involves two participant groups -adult stroke survivors and Occupational Therapists. These represent realistic and appropriate user groups for this stage of implementation research. A control group is not included, as the primary aim is not comparative effectiveness but to assess feasibility and user experience. This study will use a exploratory approach to using qualitative methods for gather insight into safety, acceptability and usability such as the System usability Scale, EQ-5D-5L and custom design Questionnaire. Quantitative methods will be used for evaluating rehabilitating and function outcomes this includes data collected by the Resynk application and the standardised Fugl Meyers assessment. The study will involve pre, post and follow up data collection for both participant groups.

Interventions

DEVICEResynk VR session

The study will use hardware and software to achieve this immersive virtual reality. The Resynk Virtual Reality programme (software) and the Meta Quest Virtual Reality Headset (hardware) will be used. Immersive virtual reality (VR) is when technology makes you feel like you're inside a different world. You wear a virtual reality headset that covers your eyes and ears, showing you a 3D world and playing matching sounds. The headset's head tracking, changing the view in the VR world as you look around. You can then interact with this virtual reality world depending on the application or game you use. The Resynk VR software launches automatically, guiding them through therapist-designed games that make rehabilitation engaging. The system uses advanced hand-tracking technology, eliminating the need for physical controllers. It detects joint movements in the hands and fingers, allowing users to perform key rehabilitation exercises such as supination, pronation, grasping, and pinching.

OTHERUsing Resynk VR on stroke survivors

The Resynk Virtual Reality programme (software) and the Meta Quest Virtual Reality Headset (hardware) will be used by Occupational therapy participants to treat the stroke survivor participants

Sponsors

Belfast Health and Social Care Trust
CollaboratorOTHER
eXRt Intelligent Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

Stroke Participants Able to provide informed consent Aged over 18 years. Evidence of stroke confirmed by medical team Newly diagnosed patients who are admitted to the acute stroke unit with a confirmed diagnosis of stroke. More than 48 hours since stroke event Patient is appropriate to participate in rehabilitation according to the treating physician or medical consultant, and able to follow simple verbal commands. Presence of an upper limb deficit identified in the NIHSS (National Institutes of Health Stroke Scale) or by a member of the medical or multidisciplinary team Residents within the Belfast health and social care trust catchment area/postcode Staff participants: Qualified Registered Occupational Therapy Staff who work in the Stroke Unit in the Royal Victoria Hospital Belfast or in the Community Stroke Team in the Belfast Health and Social Care Trust. Able to provide informed consent Aged 18 or over

Exclusion criteria

Stroke Participants: Stroke onset more than 3 months prior to study entry. Acutely medically unwell as per medical team Patient is unable to follow verbal commands or has global aphasia. Interpreters may be used to accommodate stroke survivors' communication needs. Severe illness with a life expectancy of less than 3 months (e.g., cancer, endocarditis, metastasis with an occult primary malignancy). Uncontrolled hypertension as assessed by the treating physician. Unstable angina or recent myocardial infarction. Any history of epilepsy or seizures, except for febrile seizures of childhood. Current participation in another clinical trial involving rehabilitation (e.g., recreational therapy, occupational therapy, physiotherapy) or an investigational drug that might interfere with study results. Patient is unwilling or unable to comply with the protocol or cannot/will not cooperate fully with the investigator or study personnel. Any physical health condition, mental health condition, or other medical condition or diagnosis that might confound the interpretation of results or put the patient at risk (e.g., amputation of one extremity). History of vertigo. Active delirium/significant levels of confusion Cervical artery dissection. Patients with implanted devices such as pacemakers, defibrillators, and cochlear implants. Individual currently being managed under the Mental Capacity Act Staff participants: Uncontrolled hypertension as assessed by the treating physician. Unstable angina or recent myocardial infarction Any history of epilepsy, seizures, except for febrile seizures of childhood. Current participation in another clinical trial involving rehabilitation (e.g., recreational therapy, occupational therapy, physiotherapy) or an investigational drug that might interfere with study results. Any physical health condition, mental health condition, or other medical condition or diagnosis that might confound the interpretation of results or put the patient at risk (e.g., amputation of one extremity). History of vertigo. Cervical artery dissection. Staff members with implanted devices such as pacemakers, defibrillators, and cochlear implants.

Design outcomes

Primary

MeasureTime frameDescription
System Usability ScaleDay 1 & Day 30Scale assess the usability of the resynk VR system for both arms higher score mean higher usability
Safety and Acceptability QuestionnaireDay 1 & Day 30A custom Questionnaire to evaluate the safety and acceptability of Resynk VR in both arms

Secondary

MeasureTime frameDescription
Upper limb function (Fugl-Meyer Assessment)Day 1 & Day 30The standardised Fugl meyer upper limb assessment to assess upper limb function stroke survivor arm only
Quality of life (EQ-5D-5L)Day 1 & Day 30 & Day 60Assess the quality of life of the patient before and after intervention stroke survivor arm only
self-efficacy (General Self-Efficacy Scale)Day 1 & Day 30self-efficacy is a person's perception of their ability to perform tasks stroke survivor arm only
rehabilitation intensity (resynk repetition count vs average conventional therapy based on literature)Day 1 & Day 30Compare resynk rehab intensity vs conventional to show service improvement or not, stroke survivor arm only

Countries

United Kingdom

Contacts

Primary ContactDominic Holmes, PhD
dominic@exrt.io07514575765

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026